BRCA m carriers have been shown to have a better response to platinum‐based chemotherapy, 10 , 36 and our results showed a trend of patients with BRCA m maintaining a higher response rate to platinum treatment along the progressed chemotherapy lines compared to patients without BRCA m.
← all excerpts
Prevalence and clinical characterization of BRCA1 and BRCA2 mutations in Korean patients with epithelial ovarian cancer.
1
—
—